Success Metrics

Clinical Success Rate
91.7%

Based on 11 completed trials

Completion Rate
92%(11/12)
Active Trials
11(34%)
Results Posted
55%(6 trials)
Terminated
1(3%)

Phase Distribution

Ph phase_2
7
22%
Ph phase_3
4
13%
Ph not_applicable
11
34%
Ph phase_4
2
6%
Ph phase_1
4
13%

Phase Distribution

4

Early Stage

7

Mid Stage

6

Late Stage

Phase Distribution28 total trials
Phase 1Safety & dosage
4(14.3%)
Phase 2Efficacy & side effects
7(25.0%)
Phase 3Large-scale testing
4(14.3%)
Phase 4Post-market surveillance
2(7.1%)
N/ANon-phased studies
11(39.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.6%

11 of 14 finished

Non-Completion Rate

21.4%

3 ended early

Currently Active

11

trials recruiting

Total Trials

32

all time

Status Distribution
Active(12)
Completed(11)
Terminated(3)
Other(6)

Detailed Status

Completed11
Recruiting7
unknown6
Active, not recruiting4
Withdrawn2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
32
Active
11
Success Rate
91.7%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (14.3%)
Phase 27 (25.0%)
Phase 34 (14.3%)
Phase 42 (7.1%)
N/A11 (39.3%)

Trials by Status

not_yet_recruiting13%
active_not_recruiting413%
terminated13%
withdrawn26%
completed1134%
recruiting722%
unknown619%

Recent Activity

Clinical Trials (32)

Showing 20 of 32 trialsScroll for more
NCT03244384Phase 3

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

Active Not Recruiting
NCT07061964Phase 2

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Recruiting
NCT05987241Phase 2

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Recruiting
NCT07579195Phase 1

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

Not Yet Recruiting
NCT07000084Phase 3

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

Recruiting
NCT03775265Phase 3

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Active Not Recruiting
NCT04216290Phase 2

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Active Not Recruiting
NCT04164082Phase 2

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Active Not Recruiting
NCT05796375Phase 2

Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance

Recruiting
NCT06704191Phase 1

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Recruiting
NCT03258593Phase 1

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Completed
NCT06126796

Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)

Completed
NCT05564416Phase 2

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

Withdrawn
NCT05438563Not Applicable

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

Recruiting
NCT06725212Not Applicable

Evaluation of the Water Vapor Thermal Therapy System for the Treatment of Benign Prostatic Hyperplasia

Recruiting
NCT05362539Not Applicable

Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria

Completed
NCT05260788

Mapping 3D Bladder

Withdrawn
NCT03099863Phase 4

Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection

Completed
NCT04781985Not Applicable

Prostatic Resection Cavity Stone Post Transurethral Resection of the Prostate (TURP). A Rare Case Scenario

Completed
NCT01261819Not Applicable

"Laparoscopic" Cystoscopy Versus Traditional Cystoscopy

Completed

Drug Details

Intervention Type
PROCEDURE
Total Trials
32